Genetic markers of a Munc13 protein family member,BAIAP3, are gender specifically associated with anxiety andbenzodiazepine abuse in mice and humans

Molecular Medicine

Volumn 19, Issue 1, 2013, Pages 135-148

  Wojcik, Sonja M ^a   Tantra, Martesa ^a,b   Stepniak, Beata ^a   Man, M Kwun Nok ^a,b   Müller Ribbe, Katja ^a   Begemann, Martin ^a   Ju, Anes ^a   Papiol, Sergi ^a,b   Ronnenberg, Anja ^a   Gurvich, Artem ^a   Shin, Yong ^a,c   Augustin, Iris ^a,d   Brose, Nils ^a,b   Ehrenreich, Hannelore ^a,b  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b Deutsche Forschungsgemeinschaft   (Germany)

^c INSTITUTE OF MICROELECTRONICS   (Singapore)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; BENZODIAZEPINE; BRAIN SPECIFIC ANGIOGENESIS INHIBITOR I ASSOCIATED PROTEIN 3; CHLORPROMAZINE; DIAZEPAM; FLUMAZENIL; GENOMIC DNA; MAMMALIAN UNCOORDINATED 13 PROTEIN; MIDAZOLAM; NEUROTRANSMITTER RECEPTOR; PENTETRAZOLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BAIAP3 GENE; DNA EXTRACTION; DRUG ABUSE; ELECTROPHYSIOLOGY; EXOCYTOSIS; FEMALE; GENE; GENE ACTIVITY; GENE DELETION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPOTHALAMUS; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PERIAQUEDUCTAL GRAY MATTER; PHENOTYPE; PRIORITY JOURNAL; SCHIZOPHRENIA; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TONIC CLONIC SEIZURE;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANXIETY; BEHAVIOR, ANIMAL; DIAZEPAM; FEMALE; HUMANS; HYPOTHALAMUS; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDAZOLAM; NERVE TISSUE PROTEINS; PENTYLENETETRAZOLE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHOMOTOR PERFORMANCE; SEIZURES; SEX FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84878813708     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2013.00033     Document Type: Article

References (54)

1. Kessler RC, et al. (2005) Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch. Gen. Psychiatry. 62:593-602.
2. Pasche S. (2012) Exploring the comorbidity of anxiety and substance use disorders. Curr. Psychiatry Rep. 14:176-81.
3. Swendsen J, et al. (2010) Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. Addiction. 105:1117-28.
4. Conway KP, Compton W, Stinson FS, Grant BF. (2006) Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry. 67:247-57.
5. Myrick H, Brady K. (2003) Current review of the comorbidity of affective, anxiety, and substance use disorders. Curr. Opin. Psychiatry. 16:261-70.
6. Bandelow B, et al. (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive- compulsive disorder and posttraumatic stress disorder in primary care. Int. J. Psychiatry Clin. Pract. 16:77-84.
7. Baker AL, Thornton LK, Hiles S, Hides L, Lubman DI. (2012) Psychological interventions for alcohol misuse among people with co-occurring depression or anxiety disorders: a systematic review. J. Affect. Disord. 139:217-29.
8. Hettema JM, Neale MC, Kendler KS. (2001) A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am. J. Psychiatry. 158:1568-78.
9. Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS. (2005) The structure of genetic and environmental risk factors for anxiety disorders in men and women. Arch. Gen. Psychiatry. 62:182-9.
10. Ducci F, Goldman D. (2012) The genetic basis of addictive disorders. Psychiatr. Clin. North Am. 35:495-519.
11. Hovatta I, Barlow C. (2008) Molecular genetics of anxiety in mice and men. Ann. Med. 40:92-109.
12. Hamilton SP. (2009) Linkage and association studies of anxiety disorders. Depress. Anxiety. 26:976-83.
13. Wang JC, Kapoor M, Goate AM. (2012) The genetics of substance dependence. Annu. Rev. Genomics Hum. Genet. 13:241-61.
14. Gelernter J, Kranzler HR. (2010) Genetics of drug dependence. Dialogues Clin. Neurosci. 12:77-84.
15. Buckland PR. (2008) Will we ever find the genes for addiction? Addiction. 103:1768-76.
16. Marmorstein NR. (2012) Anxiety disorders and substance use disorders: different associations by anxiety disorder. J. Anxiety Disord. 26:88-94.
17. DeMartini KS, Carey KB. (2011) The role of anxiety sensitivity and drinking motives in predicting alcohol use: a critical review. Clin. Psychol. Rev. 31:169-77.
18. Zavos HM, Gregory AM, Eley TC. (2012) Longitudinal genetic analysis of anxiety sensitivity. Dev. Psychol. 48:204-12.
19. Kushner MG, Thuras P, Abrams K, Brekke M, Stritar L. (2001) Anxiety mediates the association between anxiety sensitivity and coping-related drinking motives in alcoholism treatment patients. Addict. Behav. 26:869-85.
20. Baldwin DS, Allgulander C, Bandelow B, Ferre F, Pallanti S. (2012) An international survey of reported prescribing practice in the treatment of patients with generalised anxiety disorder. World J. Biol. Psychiatry. 13:510-6.
21. Canteras NS, Resstel LB, Bertoglio LJ, Carobrez Ade P, Guimaraes FS. (2010) Neuroanatomy of anxiety. Curr. Top. Behav. Neurosci. 2:77-96.
22. Gratacos M, et al. (2007) Candidate genes for panic disorder: insight from human and mouse genetic studies. Genes Brain Behav. 6 (Suppl. 1):2-23.
23. Koch H, Hofmann K, Brose N. (2000) Definition of Munc13-homology-domains and characterization of a novel ubiquitously expressed Munc13 isoform. Biochem. J. 349:247-53.
24. Shiratsuchi T, et al. (1998) Cloning and characterization of BAP3 (BAI-associated protein 3), a C2 domain-containing protein that interacts with BAI1. Biochem. Biophys. Res. Commun. 251:158-65.
25. Varoqueaux F, et al. (2002) Total arrest of spontaneous and evoked synaptic transmission but normal synaptogenesis in the absence of Munc13-mediated vesicle priming. Proc. Natl. Acad. Sci. U. S. A. 99:9037-42.
26. Gorman JM, Kent JM, Sullivan GM, Coplan JD. (2000) Neuroanatomical hypothesis of panic disorder, revised. Am. J. Psychiatry. 157:493-505.
27. Gross CT, Canteras NS. (2012) The many paths to fear. Nat. Rev. Neurosci. 13:651-8.
28. Wojcik SM, Brose N. (2007) Regulation of membrane fusion in synaptic excitation-secretion coupling: speed and accuracy matter. Neuron. 55:11-24.
29. Feldmann J, et al. (2003) Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 115:461-73.
30. Shirakawa R, et al. (2004) Munc13-4 is a GTPRab27- binding protein regulating dense core granule secretion in platelets. J. Biol. Chem. 279:10730-7.
31. Begemann M, et al. (2010) Modification of cognitive performance in schizophrenia by complexin 2 gene polymorphisms. Arch. Gen. Psychiatry. 67:879-88.
32. Ribbe K, et al. (2010) The cross-sectional GRAS sample: a comprehensive phenotypical data collection of schizophrenic patients. BMC Psychiatry. 10:91.
33. Ferraro TN, et al. (1999) Mapping loci for pentylenetetrazol-induced seizure susceptibility in mice. J. Neurosci. 19:6733-9.
34. American Psychiatric Association (APA). (2000) Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. 4th ed., text revision. Washington (DC): APA. 992 pp.
35. Kay SR, Fiszbein A, Opler LA. (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13:261-76.
36. Cronbach LJ. (1951) Coefficient alpha and the internal structure of tests. Psychometrika. 16:297-334.
37. Rubin DB. (1987) Multiple Imputation for Non-Response in Surveys. New York: John Wiley & Sons.
38. Stefanova N, Ovtscharoff W. (2000) Sexual dimorphism of the bed nucleus of the stria terminalis and the amygdala. Adv. Anat. Embryol. Cell Biol. 158:III-X, 1-78.
39. Qureshi IA, Mehler MF. (2010) Genetic and epigenetic underpinnings of sex differences in the brain and in neurological and psychiatric disease susceptibility. Prog. Brain Res. 186:77-95.
40. Neutel CI. (2005) The epidemiology of long-term benzodiazepine use. Int. Rev. Psychiatry. 17:189-97.
41. Pierce KA, Kirkpatrick DR. (1992) Do men lie on fear surveys? Behav. Res. Ther. 30:415-8.
42. McLean CP, Anderson ER. (2009) Brave men and timid women? A review of the gender differences in fear and anxiety. Clin. Psychol. Rev. 29:496-505.
43. Stoyanova M, Hope DA. (2012) Gender, gender roles, and anxiety: perceived confirmability of self report, behavioral avoidance, and physiological reactivity. J. Anxiety Disord. 26:206-14.
44. Tan KR, Rudolph U, Luscher C. (2011) Hooked on benzodiazepines: GABAA receptor subtypes and addiction. Trends Neurosci. 34:188-97.
45. Fenoglio KA, et al. (2007) Hypothalamic hamartoma: basic mechanisms of intrinsic epileptogenesis. Semin. Pediatr. Neurol. 14:51-9.
46. Aroniadou-Anderjaska V, Fritsch B, Qashu F, Braga MF. (2008) Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res. 78:102-16.
47. Pinto D, et al. (2005) Genome-wide linkage scan of epilepsy-related photoparoxysmal electroencephalographic response: evidence for linkage on chromosomes 7q32 and 16p13. Hum. Mol. Genet. 14:171-8.
48. de Kovel CG, et al. (2010) Whole-genome linkage scan for epilepsy-related photosensitivity: a mega-analysis. Epilepsy Res. 89:286-94.
49. Zetterstrom T, Fillenz M. (1990) Local administration of flurazepam has different effects on dopamine release in striatum and nucleus accumbens: a microdialysis study. Neuropharmacology. 29:129-34.
50. Invernizzi R, Pozzi L, Samanin R. (1991) Release of dopamine is reduced by diazepam more in the nucleus accumbens than in the caudate nucleus of conscious rats. Neuropharmacology. 30:575-8.
51. Finlay JM, Damsma G, Fibiger HC. (1992) Benzodiazepine- induced decreases in extracellular concentrations of dopamine in the nucleus accumbens after acute and repeated administration. Psychopharmacology (Berl.). 106:202-8.
52. Tan KR, et al. (2010) Neural bases for addictive properties of benzodiazepines. Nature. 463:769-74.
53. O'Brien DP, White FJ. (1987) Inhibition of nondopamine cells in the ventral tegmental area by benzodiazepines: relationship to A10 dopamine cell activity. Eur. J. Pharmacol. 142:343-54.
54. Heberlein A, Bleich S, Kornhuber J, Hillemacher T. (2008) Neuroendocrine pathways in benzodiazepine dependence: new targets for research and therapy. Hum. Psychopharmacol. 23:171-81.